Free tool
Healthcare stocks
We cover 1,248 companies in the Healthcare sector. The median market value in the group is $1.87B, measured across the 1,000 largest of them. Among those 1,000, the median move over the past trading day is +0.59%. 65% of the 964 with a 200-day average trade above it. Price change over the past year runs from −31.7% to +171.6% across the middle 80 percent of the group, with a median of +17.9%. Among those 1,000, 8 companies currently carry a tier A volume signal.
Other lists in this group
Table
1,248 of 2,199 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | $184.47B | Large cap | +32.85% |
| GILD34.SA | Gilead Sciences, Inc. | $184.17B | Large cap | −78.95% |
| GIS.DE | Gilead Sciences, Inc. | $183.56B | Large cap | +29.53% |
| PFE.DE | Pfizer Inc. | $162.65B | Large cap | +18.09% |
| PFIZ34.SA | Pfizer Inc. | $161.64B | Large cap | +11.31% |
| PFE | Pfizer Inc. | $159.42B | Large cap | +19.52% |
| DHR | Danaher Corporation | $151.82B | Large cap | +4.52% |
| DHER34.SA | Danaher Corporation | $151.72B | Large cap | −0.75% |
| DAP.DE | Danaher Corporation | $151.41B | Large cap | +5.45% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $140.77B | Large cap | +40.14% |
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | $140.14B | Large cap | −83.17% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.04B | Large cap | +42.14% |
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| BMYB34.SA | Bristol-Myers Squibb Company | $138.65B | Large cap | +40.74% |
| BRM.DE | Bristol-Myers Squibb Company | $138.39B | Large cap | +46.24% |
| IUI1.DE | Intuitive Surgical, Inc. | $133.35B | Large cap | −20.90% |
| ISRG | Intuitive Surgical, Inc. | $133.22B | Large cap | −20.62% |
| I1SR34.SA | Intuitive Surgical, Inc. | $133.21B | Large cap | −24.38% |
| SYK | Stryker Corporation | $126.81B | Large cap | −14.79% |
| S1YK34.SA | Stryker Corporation | $126.62B | Large cap | −17.50% |
| SYK.DE | STRYKER CORP. R | $126.48B | Large cap | +34.76% |
| MDTC34.SA | Medtronic plc | $117.91B | Large cap | −76.08% |
| 2M6.DE | Medtronic plc | $117.39B | Large cap | +3.67% |
| MDT | Medtronic plc | $116.66B | Large cap | +1.33% |
| SNY | Sanofi | $110.27B | Large cap | −3.11% |
| SAN.PA | Sanofi | $110.15B | Large cap | −4.49% |
| SNW.DE | Sanofi | $109.49B | Large cap | −4.28% |
| MCK | McKesson Corporation | $105.52B | Large cap | +33.71% |
| GS71.DE | GSK plc | $104.54B | Large cap | +31.93% |
| G1SK34.SA | GSK plc | $104.53B | Large cap | +28.14% |
| GSK | GSK plc | $104.29B | Large cap | +34.79% |
| GSK.L | GSK plc | $104.16B | Large cap | +28.03% |
| M1CK34.SA | McKesson Corporation | $101.65B | Large cap | −92.48% |
| HCA | HCA Healthcare, Inc. | $95.12B | Large cap | +6.96% |
| H1CA34.SA | HCA Healthcare, Inc. | $92.89B | Large cap | +3.95% |
| A58.DE | Elevance Health, Inc. | $86.73B | Large cap | −18.92% |
| E1LV34.SA | Elevance Health, Inc. | $86.53B | Large cap | +21.66% |
| ELV | Elevance Health, Inc. | $86.50B | Large cap | +29.17% |
| RGO.DE | Regeneron Pharmaceuticals, Inc. | $86.30B | Large cap | −7.35% |
| ESL.DE | EssilorLuxottica Société anonyme | $85.86B | Large cap | −38.59% |
| REGN | Regeneron Pharmaceuticals, Inc. | $85.82B | Large cap | +46.21% |
| EL.PA | EssilorLuxottica Société anonyme | $85.41B | Large cap | −37.89% |
| REGN34.SA | Regeneron Pharmaceuticals, Inc. | $85.24B | Large cap | +37.96% |
| CI | The Cigna Group | $73.81B | Large cap | −5.62% |
| C1IC34.SA | The Cigna Group | $73.40B | Large cap | −85.51% |
| CGN.DE | The Cigna Group | $73.25B | Large cap | −8.36% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $73.00B | Large cap | +12.47% |
| B1SX34.SA | Boston Scientific Corporation | $72.28B | Large cap | −88.79% |
| BSX | Boston Scientific Corporation | $72.26B | Large cap | −52.56% |
| BSX.DE | Boston Scientific Corporation | $71.57B | Large cap | −54.21% |
| MRK.DE | Merck KGaA | $70.75B | Large cap | +30.60% |
| ARGX | argenx SE | $63.78B | Large cap | +50.52% |
| M1RN34.SA | Moderna, Inc. | $63.51B | Large cap | +494.34% |
| 0QF.DE | Moderna, Inc. | $63.46B | Large cap | +461.14% |
| MRNA | Moderna, Inc. | $63.41B | Large cap | +526.55% |
| A1RG34.SA | argenx SE | $63.17B | Large cap | +44.49% |
| COR | Cencora, Inc. | $62.60B | Large cap | +14.44% |
| CSL.AX | CSL Limited | $59.98B | Large cap | −17.14% |
| 4502.T | Takeda Pharmaceutical Company Limited | $58.99B | Large cap | +39.50% |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +21.77% |
| TAKP34.SA | Takeda Pharmaceutical Company Limited | $57.23B | Large cap | +16.07% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.51B | Large cap | +71.10% |
| CAH | Cardinal Health, Inc. | $55.33B | Large cap | +64.25% |
| C1AH34.SA | Cardinal Health, Inc. | $55.24B | Large cap | +50.94% |
| BAY.WA | Bayer Aktiengesellschaft | $55.03B | Large cap | +71.25% |
| 207940.KS | Samsung Biologics Co.,Ltd. | $53.31B | Large cap | +2.60% |
| C1CO34.SA | Cencora, Inc. | $52.36B | Large cap | −12.17% |
| EW | Edwards Lifesciences Corporation | $52.32B | Large cap | +12.38% |
| BOX.DE | Becton, Dickinson and Company | $52.05B | Large cap | +2.94% |
| EWL.DE | Edwards Lifesciences Corporation | $51.93B | Large cap | +10.23% |
| SHL.DE | Siemens Healthineers AG | $51.88B | Large cap | −12.35% |
| B1DX34.SA | Becton, Dickinson and Company | $51.78B | Large cap | −113.87% |
| BDX | Becton, Dickinson and Company | $51.69B | Large cap | +26.17% |
| 7741.T | HOYA Corporation | $51.57B | Large cap | +29.26% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.24% |
| E1WL34.SA | Edwards Lifesciences Corporation | $47.29B | Large cap | −4.72% |
| MDLN | Medline Inc. | $46.69B | Large cap | −13.07% |
| HUM | Humana Inc. | $46.42B | Large cap | +32.71% |
| H1UM34.SA | Humana Inc. | $45.80B | Large cap | +24.30% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| HLN | Haleon plc | $44.77B | Large cap | +6.56% |
| H6D0.DE | Haleon plc | $44.53B | Large cap | +4.86% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.40B | Large cap | +110.26% |
| HLN.L | Haleon plc | $44.36B | Large cap | +2.08% |
| I1DX34.SA | IDEXX Laboratories, Inc. | $44.35B | Large cap | −16.38% |
| IDXX | IDEXX Laboratories, Inc. | $43.39B | Large cap | −14.24% |
| A | Agilent Technologies, Inc. | $43.33B | Large cap | +30.69% |
| T1EV34.SA | Teva Pharmaceutical Industries Limited | $43.18B | Large cap | +94.70% |
| IX1.DE | IDEXX Laboratories, Inc. | $43.12B | Large cap | +17.97% |
| IQV | IQVIA Holdings Inc. | $42.70B | Large cap | +37.97% |
| QTS.DE | IQVIA Holdings Inc. | $42.69B | Large cap | −3.91% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% |
| V2EE34.SA | Veeva Systems Inc. | $41.01B | Large cap | −16.69% |
| WAT | Waters Corporation | $40.69B | Large cap | +38.63% |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.62B | Large cap | +58.81% |
| VEEV | Veeva Systems Inc. | $40.09B | Large cap | −13.47% |
| VEE.DE | Veeva System Inc. R | $40.06B | Large cap | +13.96% |
| A1GI34.SA | Agilent Technologies, Inc. | $39.64B | Large cap | −77.11% |
| WATC34.SA | Waters Corporation | $36.36B | Large cap | +24.76% |
| ALC | Alcon Inc. | $35.47B | Large cap | −8.71% |
| RPRX | Royalty Pharma plc | $35.44B | Large cap | +75.10% |
| 2U3.DE | Alcon Inc. | $35.35B | Large cap | −10.05% |
| DC4.DE | DexCom, Inc. | $34.19B | Large cap | +21.55% |
| RMD | ResMed Inc. | $34.13B | Large cap | −16.58% |
| I1LM34.SA | Illumina, Inc. | $34.11B | Large cap | +113.13% |
| RMD.AX | ResMed Inc. | $34.05B | Large cap | −24.73% |
| ILU.DE | Illumina, Inc. | $34.04B | Large cap | +119.28% |
| ILMN | Illumina, Inc. | $33.97B | Large cap | +125.76% |
| D1EX34.SA | DexCom, Inc. | $33.83B | Large cap | +11.74% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +17.38% |
| GEHC | GE HealthCare Technologies Inc. | $33.62B | Large cap | −0.78% |
| 4568.T | Daiichi Sankyo Company, Limited | $33.36B | Large cap | −15.95% |
| IDP.DE | Biogen Inc. | $32.80B | Large cap | +57.35% |
| C1NC34.SA | Centene Corporation | $32.65B | Large cap | +116.81% |
| BIIB | Biogen Inc. | $32.62B | Large cap | +61.90% |
| BIIB34.SA | Biogen Inc. | $32.56B | Large cap | +47.86% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.12B | Large cap | −45.88% |
| CNC | Centene Corporation | $32.11B | Large cap | +123.52% |
| ZTS | Zoetis Inc. | $31.94B | Large cap | −49.59% |
| 068270.KS | Celltrion, Inc. | $31.91B | Large cap | +13.47% |
| Z1TS34.SA | Zoetis Inc. | $31.90B | Large cap | −52.14% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $31.87B | Large cap | −11.75% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | $31.78B | Large cap | −49.89% |
| ZOE.DE | Zoetis Inc. | $31.72B | Large cap | −50.09% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.15B | Large cap | +1.55% |
| 22UA.DE | BioNTech SE | $29.53B | Large cap | +8.53% |
| B1NT34.SA | BioNTech SE | $28.89B | Large cap | +3.26% |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% |
| MTD | Mettler-Toledo International Inc. | $28.10B | Large cap | +8.72% |
| MTO.DE | Mettler-Toledo International Inc. | $27.84B | Large cap | +13.15% |
| 4503.T | Astellas Pharma Inc. | $27.40B | Large cap | +56.44% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +23.25% |
| R1MD34.SA | ResMed Inc. | $27.30B | Large cap | −38.24% |
| INSM | Insmed Incorporated | $27.07B | Large cap | −3.45% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.70% |
| PHG | Koninklijke Philips N.V. | $26.81B | Large cap | +3.60% |
| PHI1.DE | Koninklijke Philips N.V. | $26.73B | Large cap | +2.84% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| ROIV | Roivant Sciences Ltd. | $26.26B | Large cap | +213.32% |
| I1NC34.SA | Incyte Corporation | $25.83B | Large cap | +41.91% |
| WST | West Pharmaceutical Services, Inc. | $24.52B | Large cap | +41.31% |
| 4543.T | Terumo Corporation | $24.11B | Large cap | −1.19% |
| SIG.AX | Sigma Healthcare Limited | $23.62B | Large cap | −5.33% |
| STE | STERIS plc | $23.05B | Large cap | −4.35% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $22.07B | Large cap | +10.02% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $22.06B | Large cap | +10.46% |
| GH | Guardant Health, Inc. | $21.90B | Large cap | +166.52% |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +54.57% |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% |
| GE9.DE | GENMAB AS N | $21.11B | Large cap | −14.41% |
| GMAB.CO | Genmab A/S | $21.08B | Large cap | +33.08% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.88B | Large cap | +26.10% |
| S1TE34.SA | STERIS plc | $19.75B | Large cap | −18.78% |
| VTRS | Viatris Inc. | $19.20B | Large cap | +62.88% |
| VIA.DE | Viatris Inc. | $19.14B | Large cap | +62.09% |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.12B | Large cap | −5.86% |
| QS51.DE | Straumann Holding AG | $18.25B | Large cap | +0.41% |
| Z1BH34.SA | Zimmer Biomet Holdings, Inc. | $18.07B | Large cap | −5.04% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $17.32B | Large cap | +54.48% |
| MEDP | Medpace Holdings, Inc. | $17.31B | Large cap | +31.55% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +108.87% |
| ASND | Ascendis Pharma A/S | $16.59B | Large cap | +32.89% |
| COLO-B.CO | Coloplast A/S | $16.31B | Large cap | −20.81% |
| CBHD.DE | Coloplast A/S | $16.19B | Large cap | +7.28% |
| IPN.PA | Ipsen S.A. | $16.01B | Large cap | +39.21% |
| BBIO | BridgeBio Pharma, Inc. | $15.85B | Large cap | +70.01% |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.80B | Large cap | +13.60% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.72B | Large cap | +22.06% |
| N1BI34.SA | Neurocrine Biosciences, Inc. | $15.69B | Large cap | +7.58% |
| 4507.T | Shionogi & Co., Ltd. | $15.68B | Large cap | +17.95% |
| SOLV | Solventum Corporation | $15.59B | Large cap | +25.92% |
| NBIX | Neurocrine Biosciences, Inc. | $15.59B | Large cap | +14.46% |
| RDOR3.SA | Rede D'Or São Luiz S.A. | $15.25B | Large cap | +5.51% |
| C1OO34.SA | The Cooper Companies, Inc. | $15.12B | Large cap | −0.30% |
| ERF.PA | Eurofins Scientific SE | $14.91B | Large cap | +13.76% |
| ESF0.DE | Eurofins Scientific SE | $14.63B | Large cap | +11.02% |
| 7733.T | Olympus Corporation | $14.46B | Large cap | +26.42% |
| COO | The Cooper Companies, Inc. | $14.25B | Large cap | −0.60% |
| CRL | Charles River Laboratories International, Inc. | $14.21B | Large cap | +81.37% |
| PME.AX | Pro Medicus Limited | $14.09B | Large cap | −38.33% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +35.78% |
| B1AX34.SA | Baxter International Inc. | $13.60B | Large cap | +2.30% |
| BAX | Baxter International Inc. | $13.59B | Large cap | +7.91% |
| ICLR | ICON Public Limited Company | $13.38B | Large cap | −1.65% |
| CORT | Corcept Therapeutics Incorporated | $13.36B | Large cap | +79.56% |
| ORNBV.HE | Orion Oyj | $13.29B | Large cap | +16.59% |
| ORNAV.HE | Orion Oyj | $13.24B | Large cap | +17.12% |
| S1NN34.SA | Smith & Nephew plc | $12.87B | Large cap | −20.44% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.80B | Large cap | +13.03% |
| PEN | Penumbra, Inc. | $12.75B | Large cap | +22.79% |
| FME.DE | Fresenius Medical Care AG | $12.66B | Large cap | −3.50% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.60B | Large cap | +2.09% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +6.36% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +329.16% |
| FMS | Fresenius Medical Care AG | $12.51B | Large cap | −3.29% |
| R1VT34.SA | Revvity, Inc. | $12.50B | Large cap | +22.81% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +51.39% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −9.45% |
| SNN | Smith & Nephew plc | $12.23B | Large cap | −19.49% |
| ELAN | Elanco Animal Health Incorporated | $12.20B | Large cap | +41.03% |
| SN.L | Smith & Nephew plc | $12.20B | Large cap | −21.69% |
| EHC | Encompass Health Corporation | $11.85B | Large cap | −1.16% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.83B | Large cap | +24.24% |
| A1LG34.SA | Align Technology, Inc. | $11.51B | Large cap | +7.83% |
| DVA | DaVita Inc. | $11.41B | Large cap | +29.47% |
| ALGN | Align Technology, Inc. | $11.34B | Large cap | +10.11% |
| BTSG | BrightSpring Health Services, Inc. | $11.32B | Large cap | +137.67% |
| AFW.DE | Align Technology, Inc. | $11.31B | Large cap | −54.37% |
| TECH | Bio-Techne Corporation | $11.27B | Large cap | +28.12% |
| T1CH34.SA | Bio-Techne Corporation | $11.23B | Large cap | +23.42% |
| GMED | Globus Medical, Inc. | $11.14B | Large cap | +35.16% |
| DVAI34.SA | DaVita Inc. | $11.11B | Large cap | +15.68% |
| I1QV34.SA | IQVIA Holdings Inc. | $10.82B | Large cap | −67.19% |
| CYTK | Cytokinetics, Incorporated | $10.77B | Large cap | +109.29% |
| AXSM | Axsome Therapeutics, Inc. | $10.76B | Large cap | +76.67% |
| GKOS | Glaukos Corporation | $10.70B | Large cap | +98.13% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
| IONS | Ionis Pharmaceuticals, Inc. | $10.56B | Large cap | +52.01% |
| KRYS | Krystal Biotech, Inc. | $10.54B | Large cap | +142.69% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +202.82% |
| BIO | Bio-Rad Laboratories, Inc. | $10.45B | Large cap | +31.26% |
| ENSG | The Ensign Group, Inc. | $10.43B | Large cap | +5.44% |
| ABVX.PA | ABIVAX Société Anonyme | $10.42B | Large cap | +42.59% |
| MOH | Molina Healthcare, Inc. | $10.42B | Large cap | +13.96% |
| BIM.PA | bioMérieux S.A. | $10.40B | Large cap | −37.52% |
| UHS | Universal Health Services, Inc. | $10.40B | Large cap | −4.14% |
| ABVX | ABIVAX Société Anonyme | $10.29B | Large cap | +52.25% |
| RDY | Dr. Reddy's Laboratories Limited | $10.28B | Large cap | −14.66% |
| PRAX | Praxis Precision Medicines, Inc. | $10.28B | Large cap | +684.02% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +49.84% |
| HSIC | Henry Schein, Inc. | $10.21B | Large cap | +30.93% |
| U1HS34.SA | Universal Health Services, Inc. | $10.21B | Large cap | −10.02% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +265.05% |
| RHCPA.AX | Ramsay Health Care Limited | $10.16B | Large cap | +0.44% |
| PTGX | Protagonist Therapeutics, Inc. | $10.01B | Large cap | +164.75% |
| R1DY34.SA | Dr. Reddy's Laboratories Limited | $9.95B | Mid cap | −21.76% |
| PODD | Insulet Corporation | $9.92B | Mid cap | −56.52% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| AVTR | Avantor, Inc. | $9.75B | Mid cap | +9.16% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +85.10% |
| TWST | Twist Bioscience Corporation | $9.50B | Mid cap | +452.83% |
| WDH1.DE | Demant A/S | $9.39B | Mid cap | −5.53% |
| DEMANT.CO | Demant A/S | $9.37B | Mid cap | +17.33% |
| SYRE | Spyre Therapeutics, Inc. | $9.32B | Mid cap | +547.53% |
| KRK.WA | Krka, d. d. | $9.12B | Mid cap | +31.52% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +100.62% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| IMVT | Immunovant, Inc. | $8.95B | Mid cap | +192.14% |
| QIA.DE | Qiagen N.V. | $8.85B | Mid cap | −11.42% |
| HQY | HealthEquity, Inc. | $8.83B | Mid cap | +20.55% |
| 4523.T | Eisai Co., Ltd. | $8.67B | Mid cap | +9.74% |
| BRKR | Bruker Corporation | $8.66B | Mid cap | +64.93% |
| ATR | AptarGroup, Inc. | $8.57B | Mid cap | −2.35% |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.51B | Mid cap | +3.09% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.48B | Mid cap | +96.32% |
| TXG | 10x Genomics, Inc. | $8.43B | Mid cap | +359.99% |
| ALKS | Alkermes plc | $8.26B | Mid cap | +69.69% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +14.26% |
| 6869.T | Sysmex Corporation | $7.42B | Mid cap | +5.65% |
| HIMS | Hims & Hers Health, Inc. | $7.41B | Mid cap | −26.15% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +62.22% |
| 2413.T | M3, Inc. | $7.39B | Mid cap | −20.12% |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | −27.21% |
| RHC.AX | Ramsay Health Care Limited | $7.33B | Mid cap | +18.74% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +63.19% |
| ALK-B.CO | ALK-Abelló A/S | $7.23B | Mid cap | +8.24% |
| SHL.AX | Sonic Healthcare Limited | $7.20B | Mid cap | −11.60% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +19.61% |
| SRRK | Scholar Rock Holding Corporation | $7.09B | Mid cap | +74.77% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +21.56% |
| PACS | PACS Group, Inc. | $7.00B | Mid cap | +272.69% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| 3391.T | Tsuruha Holdings Inc. | $6.89B | Mid cap | +8.33% |
| 0126Z0.KS | SAMSUNG EPIS HOLDINGS | $6.82B | Mid cap | +13.26% |
| ORKA | Oruka Therapeutics, Inc. | $6.74B | Mid cap | +601.72% |
| 7747.T | Asahi Intecc Co., Ltd. | $6.68B | Mid cap | +58.61% |
| RADL3.SA | Raia Drogasil S.A. | $6.65B | Mid cap | +12.04% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| HLUN-B.CO | H. Lundbeck A/S | $6.61B | Mid cap | +5.61% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| HLUN-A.CO | H. Lundbeck A/S | $6.55B | Mid cap | +26.06% |
| BLTE | Belite Bio, Inc | $6.51B | Mid cap | +154.13% |
| 3088.T | MatsukiyoCocokara & Co. | $6.45B | Mid cap | −14.17% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| COH.AX | Cochlear Limited | $6.38B | Mid cap | −53.16% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +168.53% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +138.24% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.24B | Mid cap | +93.10% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.17B | Mid cap | +142.74% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.72% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| BLCO.TO | Bausch + Lomb Corporation | $6.15B | Mid cap | +18.08% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.13B | Mid cap | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +378.90% |
| STVN | Stevanato Group S.p.A. | $6.08B | Mid cap | +3.23% |
| TVTX | Travere Therapeutics, Inc. | $6.06B | Mid cap | +288.91% |
| CTEC.L | Convatec Group PLC | $6.06B | Mid cap | −2.30% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +10.45% |
| DFTX | Definium Therapeutics, Inc. | $6.02B | Mid cap | +354.92% |
| T1FX34.SA | Teleflex Incorporated | $6.00B | Mid cap | +0.29% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +36.58% |
| TFX | Teleflex Incorporated | $5.94B | Mid cap | +10.85% |
| CRSP | CRISPR Therapeutics AG | $5.89B | Mid cap | +12.51% |
| XENE | Xenon Pharmaceuticals Inc. | $5.85B | Mid cap | +58.42% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −19.07% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.62B | Mid cap | +77.42% |
| MMED | MiniMed Group, Inc. | $5.60B | Mid cap | +2.33% |
| SHC | Sotera Health Company | $5.57B | Mid cap | +19.04% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | +3.32% |
| GRFS | Grifols, S.A. | $5.44B | Mid cap | −17.62% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.23B | Mid cap | +20.73% |
| HAE | Haemonetics Corporation | $4.93B | Mid cap | +96.13% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +102.62% |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $4.89B | Mid cap | −14.48% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +209.16% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +127.83% |
| 000100.KS | Yuhan Corporation | $4.67B | Mid cap | −25.59% |
| WAY | Waystar Holding Corp. | $4.64B | Mid cap | −32.56% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.63B | Mid cap | −11.37% |
| ICUI | ICU Medical, Inc. | $4.56B | Mid cap | +44.85% |
| OBCK.DE | Ottobock SE & Co. KGaA I | $4.51B | Mid cap | −0.82% |
| DOCS | Doximity, Inc. | $4.51B | Mid cap | −62.74% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $4.47B | Mid cap | +80.49% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +49.74% |
| NVST | Envista Holdings Corporation | $4.39B | Mid cap | +30.07% |
| LIVN | LivaNova PLC | $4.37B | Mid cap | +40.92% |
| HTFL | Heartflow, Inc. | $4.34B | Mid cap | +67.19% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.26% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.24B | Mid cap | +49.81% |
| ADPT | Adaptive Biotechnologies Corporation | $4.19B | Mid cap | +107.18% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| ANN.AX | Ansell Limited | $4.17B | Mid cap | +22.31% |
| 4506.T | Sumitomo Pharma Co., Ltd. | $4.16B | Mid cap | −2.73% |
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| MANE | Veradermics, Incorporated | $4.11B | Mid cap | +171.13% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −25.71% |
| ABCL | AbCellera Biologics Inc. | $4.05B | Mid cap | +195.51% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.04B | Mid cap | −0.90% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| VKTX | Viking Therapeutics, Inc. | $3.99B | Mid cap | +32.19% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +60.12% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| MCOV-B.ST | Medicover AB (publ) | $3.91B | Mid cap | −10.12% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.91B | Mid cap | −12.72% |
| BBZA.DE | BB Biotech AG | $3.90B | Mid cap | +7.22% |
| 000105.KS | Yuhan Corporation | $3.88B | Mid cap | −31.05% |
| CAMX.ST | Camurus AB (publ) | $3.87B | Mid cap | −14.52% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| FIE.DE | Fielmann Group AG | $3.85B | Mid cap | −30.39% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.80B | Mid cap | +22.85% |
| 7459.T | MediPal Holdings Corporation | $3.77B | Mid cap | +14.74% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +150.69% |
| OGN | Organon & Co. | $3.61B | Mid cap | +52.78% |
| A2LC34.SA | Alcon Inc. | $3.57B | Mid cap | −12.91% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +168.82% |
| QURE | uniQure N.V. | $3.54B | Mid cap | +228.30% |
| OPCH | Option Care Health, Inc. | $3.54B | Mid cap | −15.75% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| NHC | National HealthCare Corporation | $3.52B | Mid cap | +103.48% |
| PLSE | Pulse Biosciences, Inc. | $3.50B | Mid cap | +197.94% |
| ZEAL.CO | Zealand Pharma A/S | $3.48B | Mid cap | −27.05% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.33B | Mid cap | +275.00% |
| MBX | MBX Biosciences, Inc. | $3.30B | Mid cap | +394.02% |
| 3349.T | COSMOS Pharmaceutical Corporation | $3.27B | Mid cap | −27.10% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +10.69% |
| AFX.DE | Carl Zeiss Meditec AG | $3.26B | Mid cap | −23.23% |
| WRBY | Warby Parker Inc. | $3.24B | Mid cap | −0.61% |
| BIOA-B.ST | BioArctic AB (publ) | $3.24B | Mid cap | +20.03% |
| CLDX | Celldex Therapeutics, Inc. | $3.24B | Mid cap | +87.96% |
| TMDX | TransMedics Group, Inc. | $3.23B | Mid cap | −18.59% |
| VIRP.PA | Virbac SA | $3.22B | Mid cap | −2.81% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +88.75% |
| AMBU-B.CO | Ambu A/S | $3.20B | Mid cap | −19.61% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.20B | Mid cap | +26.21% |
| 7649.T | Sugi Holdings Co.,Ltd. | $3.19B | Mid cap | −28.33% |
| IRON | Disc Medicine, Inc. | $3.16B | Mid cap | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +58.44% |
| ASKER.ST | Asker Healthcare Group AB (publ) | $3.03B | Mid cap | −22.60% |
| HYPE3.SA | Hypera S.A. | $2.98B | Mid cap | −4.08% |
| ALMS | Alumis Inc. | $2.98B | Mid cap | +388.98% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +82.91% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| BKD | Brookdale Senior Living Inc. | $2.91B | Mid cap | +59.90% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| ALHC | Alignment Healthcare, Inc. | $2.82B | Mid cap | −12.77% |
| ACHC | Acadia Healthcare Company, Inc. | $2.78B | Mid cap | +34.73% |
| 9989.T | Sundrug Co.,Ltd. | $2.76B | Mid cap | −17.00% |
| RGC | Regencell Bioscience Holdings Limited | $2.74B | Mid cap | −54.89% |
| VRDN | Viridian Therapeutics, Inc. | $2.74B | Mid cap | +30.21% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +56.96% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| EBO.AX | EBOS Group Limited | $2.72B | Mid cap | −35.38% |
| PRVA | Privia Health Group, Inc. | $2.71B | Mid cap | −0.93% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +237.59% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +298.43% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.62B | Mid cap | +2.09% |
| PHVS | Pharvaris N.V. | $2.62B | Mid cap | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −9.60% |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% |
| B72.DE | AtaiBeckley Inc. | $2.60B | Mid cap | +57.16% |
| CURA.TO | Curaleaf Holdings, Inc. | $2.60B | Mid cap | +225.42% |
| EMEIS.PA | EMEIS | $2.60B | Mid cap | +10.18% |
| PGEN | Precigen, Inc. | $2.60B | Mid cap | +82.91% |
| BV3.DE | BAVARIAN NORDIC N | $2.59B | Mid cap | +14.47% |
| BAVA.CO | Bavarian Nordic A/S | $2.58B | Mid cap | −10.13% |
| 2784.T | Alfresa Holdings Corporation | $2.57B | Mid cap | +7.97% |
| TRVI | Trevi Therapeutics, Inc. | $2.56B | Mid cap | +146.57% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +65.32% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% |
| BHC.TO | Bausch Health Companies Inc. | $2.52B | Mid cap | −8.00% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +17.16% |
| BHC | Bausch Health Companies Inc. | $2.50B | Mid cap | −7.81% |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.50B | Mid cap | +6.99% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +316.68% |
| ATRC | AtriCure, Inc. | $2.48B | Mid cap | +28.65% |
| PBH | Prestige Consumer Healthcare Inc. | $2.46B | Mid cap | −21.64% |
| RAPP | Rapport Therapeutics, Inc. | $2.46B | Mid cap | +249.76% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.44B | Mid cap | +63.50% |
| ONT.L | Oxford Nanopore Technologies plc | $2.44B | Mid cap | −14.60% |
| DMP.DE | Dermapharm Holding SE | $2.43B | Mid cap | +14.86% |
| BFLY | Butterfly Network, Inc. | $2.41B | Mid cap | +483.23% |
| OCUL | Ocular Therapeutix, Inc. | $2.39B | Mid cap | −8.34% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +42.20% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +37.69% |
| MLYS | Mineralys Therapeutics, Inc. | $2.32B | Mid cap | +78.70% |
| 009420.KS | Hanall Biopharma Co., Ltd. | $2.32B | Mid cap | +108.57% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.32B | Mid cap | +46.03% |
| ALMR | Alamar Biosciences, Inc. | $2.29B | Mid cap | +50.09% |
| GENB | Generate Biomedicines, Inc. | $2.27B | Mid cap | +61.11% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.27B | Mid cap | +4.09% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| EKTA-B.ST | Elekta AB (publ) | $2.27B | Mid cap | +19.21% |
| ADUS | Addus HomeCare Corporation | $2.26B | Mid cap | +3.81% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.26B | Mid cap | +10.13% |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | −3.82% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.23B | Mid cap | +38.03% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| ZBIO | Zenas BioPharma, Inc. | $2.20B | Mid cap | +103.93% |
| CLOV | Clover Health Investments, Corp. | $2.19B | Mid cap | +56.14% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +58.21% |
| XRAY | DENTSPLY SIRONA Inc. | $2.19B | Mid cap | −21.70% |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| EXE.TO | Extendicare Inc. | $2.18B | Mid cap | +147.28% |
| BHVN | Biohaven Ltd. | $2.17B | Mid cap | −3.75% |
| 9987.T | Suzuken Co., Ltd. | $2.17B | Mid cap | −11.16% |
| STOK | Stoke Therapeutics, Inc. | $2.16B | Mid cap | +77.32% |
| CLOV34.SA | Clover Health Investments, Corp. | $2.15B | Mid cap | +44.32% |
| ESTA | Establishment Labs Holdings Inc. | $2.15B | Mid cap | +77.45% |
| GN.CO | GN Store Nord A/S | $2.15B | Mid cap | −19.72% |
| KLRA | Kailera Therapeutics, Inc. | $2.14B | Mid cap | −31.73% |
| ADMA | ADMA Biologics, Inc. | $2.14B | Mid cap | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $2.14B | Mid cap | +195.71% |
| 302440.KS | SK bioscience Co.,Ltd. | $2.13B | Mid cap | −22.23% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| HCM.L | HUTCHMED (China) Limited | $2.12B | Mid cap | −21.24% |
| NANO.PA | Nanobiotix S.A. | $2.12B | Mid cap | +341.09% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| ALIF-B.ST | AddLife AB (publ) | $2.09B | Mid cap | −7.56% |
| GNS.L | Genus plc | $2.08B | Mid cap | −13.32% |
| NEU.AX | Neuren Pharmaceuticals Limited | $2.08B | Mid cap | +18.47% |
| PIII | P3 Health Partners Inc. | $2.06B | Mid cap | +35.72% |
| CMPS | COMPASS Pathways plc | $2.06B | Mid cap | +224.89% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +26.87% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +78.59% |
| TSHA | Taysha Gene Therapies, Inc. | $2.02B | Mid cap | +112.33% |
| PRGO | Perrigo Company plc | $2.01B | Mid cap | −36.97% |
| EMBLA.CO | Embla Medical hf | $2.00B | Mid cap | −5.76% |
| SRPT | Sarepta Therapeutics, Inc. | $2.00B | Small cap | +4.76% |
| GHRS | GH Research PLC | $1.99B | Small cap | +119.42% |
| PGNY | Progyny, Inc. | $1.98B | Small cap | +9.98% |
| S1RP34.SA | Sarepta Therapeutics, Inc. | $1.98B | Small cap | −2.43% |
| VIMIAN.ST | Vimian Group AB (publ) | $1.97B | Small cap | +8.44% |
| SNDA | Sonida Senior Living, Inc. | $1.97B | Small cap | +57.21% |
| FLRY3.SA | Fleury S.A. | $1.97B | Small cap | +39.13% |
| ZYME | Zymeworks Inc. | $1.96B | Small cap | +88.54% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $1.95B | Small cap | −9.02% |
| LKFT | Lakefront Biotherapeutics NV | $1.94B | Small cap | −5.53% |
| SEPN | Septerna, Inc. | $1.93B | Small cap | +245.32% |
| IMCR | Immunocore Holdings plc | $1.93B | Small cap | +14.76% |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.91B | Small cap | −26.29% |
| NTLA | Intellia Therapeutics, Inc. | $1.89B | Small cap | +18.72% |
| DMRA | Damora Therapeutics, Inc. | $1.89B | Small cap | +800.59% |
| GXE.DE | Lakefront Biotherapeutics NV | $1.89B | Small cap | −44.50% |
| ALVO-SDB.ST | Alvotech SDB | $1.87B | Small cap | −34.75% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.